A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2023-07-15
Adverse events
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-10-03 (study day 65); relationship: not assessed
Grade 3 Constipation — outcome: UNKNOWN; onset 2024-01-28 (study day 182); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-12 (study day 197); relationship: N
Grade 1 Thrombocytopenia — outcome: UNKNOWN; onset 2024-02-19 (study day 204); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-11 (study day 225); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-12-10 (study day 499); relationship: not assessed
Data queries
No data queries.